The University of Southampton
University of Southampton Institutional Repository

Newer therapies for asthma: a focus on anti-IgE

Newer therapies for asthma: a focus on anti-IgE
Newer therapies for asthma: a focus on anti-IgE
The prevalence of asthma and other allergic disorders has been on the increase not only in the western world but also in the developing countries. This increasing prevalence has lead research into the discovery and development of various new therapeutic strategies. The improved understanding about the pathophysiology of asthma has prompted the developments of novel molecules to tackle this problem. These include newer phosphodiesterase inhibitors, cytokine modulation strategies, allergen immunotherapy, and anti-IgE.
Immunoglobulin E plays a major role in airway inflammation in asthma. Omalizumab, a novel humanised monoclonal antibody directed against the high affinity FcepsilonRI portion of the IgE has shown a lot of promise in the control of asthma symptoms and as a steroid sparing agent in the management of allergic asthma. This new molecule has an excellent safety profile and could play an important role in the management of patients with severe asthma. This review gives a brief overview of the newer therapies under investigation with special reference to omalizumab in the treatment of allergic asthma.
asthma, di, th, prevalence, hypersensitivity, receptors, ige, dt, drug evaluation, human
0377-9343
107-115
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Babu, K.S. and Holgate, S.T. (2002) Newer therapies for asthma: a focus on anti-IgE. The Indian Journal of Chest Diseases & Allied Sciences, 44 (2), 107-115.

Record type: Article

Abstract

The prevalence of asthma and other allergic disorders has been on the increase not only in the western world but also in the developing countries. This increasing prevalence has lead research into the discovery and development of various new therapeutic strategies. The improved understanding about the pathophysiology of asthma has prompted the developments of novel molecules to tackle this problem. These include newer phosphodiesterase inhibitors, cytokine modulation strategies, allergen immunotherapy, and anti-IgE.
Immunoglobulin E plays a major role in airway inflammation in asthma. Omalizumab, a novel humanised monoclonal antibody directed against the high affinity FcepsilonRI portion of the IgE has shown a lot of promise in the control of asthma symptoms and as a steroid sparing agent in the management of allergic asthma. This new molecule has an excellent safety profile and could play an important role in the management of patients with severe asthma. This review gives a brief overview of the newer therapies under investigation with special reference to omalizumab in the treatment of allergic asthma.

Full text not available from this repository.

More information

Published date: 2002
Keywords: asthma, di, th, prevalence, hypersensitivity, receptors, ige, dt, drug evaluation, human

Identifiers

Local EPrints ID: 26917
URI: http://eprints.soton.ac.uk/id/eprint/26917
ISSN: 0377-9343
PURE UUID: 0a20cd2a-da97-4ee8-897b-e25bf5a2bfd2

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 06 Oct 2020 23:44

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×